475 related articles for article (PubMed ID: 15823718)
1. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease.
Takeuchi M; Sato T; Takino J; Kobayashi Y; Furuno S; Kikuchi S; Yamagishi S
Med Hypotheses; 2007; 69(6):1358-66. PubMed ID: 17888585
[TBL] [Abstract][Full Text] [Related]
3. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1208-10. PubMed ID: 15823719
[TBL] [Abstract][Full Text] [Related]
4. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
[TBL] [Abstract][Full Text] [Related]
6. Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer's disease?
Yamagishi S; Inagaki Y; Takeuchi M; Sasaki N
Med Hypotheses; 2004; 63(1):115-7. PubMed ID: 15193361
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus.
Valente T; Gella A; Fernàndez-Busquets X; Unzeta M; Durany N
Neurobiol Dis; 2010 Jan; 37(1):67-76. PubMed ID: 19778613
[TBL] [Abstract][Full Text] [Related]
8. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
Takeuchi M; Yamagishi S
Curr Pharm Des; 2008; 14(10):973-8. PubMed ID: 18473848
[TBL] [Abstract][Full Text] [Related]
9. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease.
Takeuchi M; Yamagishi S
J Alzheimers Dis; 2009; 16(4):845-58. PubMed ID: 19387117
[TBL] [Abstract][Full Text] [Related]
10. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
[TBL] [Abstract][Full Text] [Related]
11. Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo.
Takeuchi M; Yamagishi S
Med Hypotheses; 2004; 63(3):453-5. PubMed ID: 15288367
[TBL] [Abstract][Full Text] [Related]
12. Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease.
Choei H; Sasaki N; Takeuchi M; Yoshida T; Ukai W; Yamagishi S; Kikuchi S; Saito T
Acta Neuropathol; 2004 Sep; 108(3):189-93. PubMed ID: 15221334
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species.
Ko SY; Lin YP; Lin YS; Chang SS
Free Radic Biol Med; 2010 Aug; 49(3):474-80. PubMed ID: 20471471
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury.
Ikonomovic MD; Uryu K; Abrahamson EE; Ciallella JR; Trojanowski JQ; Lee VM; Clark RS; Marion DW; Wisniewski SR; DeKosky ST
Exp Neurol; 2004 Nov; 190(1):192-203. PubMed ID: 15473992
[TBL] [Abstract][Full Text] [Related]
17. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
18. The relationship between Alzheimer's disease and diabetes: Type 3 diabetes?
Kroner Z
Altern Med Rev; 2009 Dec; 14(4):373-9. PubMed ID: 20030463
[TBL] [Abstract][Full Text] [Related]
19. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides.
Mruthinti S; Buccafusco JJ; Hill WD; Waller JL; Jackson TW; Zamrini EY; Schade RF
Neurobiol Aging; 2004 Sep; 25(8):1023-32. PubMed ID: 15212827
[TBL] [Abstract][Full Text] [Related]
20. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H
Med Hypotheses; 2007; 69(2):338-40. PubMed ID: 17329034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
